Bill
HB 4681
The bill would create a state-level civil liability framework allowing individuals to sue vaccine manufacturers in West Virginia for injuries alleged to be caused by Covid-19 vacci
Title: To create state civil liability for pharmaceutical companies for vaccine injuries from the Covid-19 vaccines
Jurisdiction: West Virginia
Status and Timeline
- Action History: Filed for introduction on 2026-01-21; referred to House Judiciary; introduced in House on 2026-01-21.
- Sponsorship: Primary sponsors and co-sponsors include Elías Coop-González, Larry Kump, Chris Anders, Lisa White, Laura Kimble, and Corby Dillon.
Note: The provided bill text appears to be incomplete or corrupted in the source materials, but the stated title and available action history indicate the bill’s core intent.
1) Purpose and Intent
- The bill proposes creating a state-level civil liability framework that would allow individuals to pursue civil claims against pharmaceutical companies specifically for injuries alleged to be caused by Covid-19 vaccines.
- In essence, it would establish a statutory basis for civil lawsuits against vaccine manufacturers or related pharmaceutical entities within West Virginia for vaccine-related injuries.
2) Key Provisions and Changes (as implied by the title)
- Creation of a civil liability regime: The measure would authorize civil actions by private individuals (or potentially certain classes of claimants) against pharmaceutical companies in connection with Covid-19 vaccine injuries.
- Scope of liability: It would define the types of injuries or adverse events covered, and the conditions under which a manufacturer could be held liable (for example, causation standards, fault requirements, or product defect theories).
- Standards and defenses: The bill would likely specify the legal standards applicable to such claims (e.g., negligence, strict liability, product liability theories) and potential defenses available to manufacturers (e.g., compliance with federal vaccine laws, government preemption, or assumption of risk).
- Damages and remedies: Provisions would address the range of possible damages (economic, noneconomic, medical expenses, lost wages, pain and suffering) and any caps, offsets, or limitations.
- Statute of limitations: The bill could set time limits for filing claims.
- Procedural rules: The measure might outline procedural pathways for these claims (jurisdiction, venue, discovery rules, expert requirements, and any special considerations given vaccine injury cases).
- Relationship to existing law: It would create a parallel state-law remedy and specify that it is distinct from federal vaccine-injury programs (e.g., the National Vaccine Injury Compensation Program), including how concurrent or exclusive remedies would operate.
3) Who or What Would Be Affected
- Primary: Pharmaceutical companies or their divisions involved in Covid-19 vaccine development, production, sourcing, distribution, or marketing.
- Indirect: Healthcare providers, insurers, and patients who might be claimants; state courts that would hear such civil actions.
- Impacted Sectors: The vaccine manufacturing, pharmaceutical, and related biotechnologies sectors, as well as health care litigation dynamics in West Virginia.
4) Procedural and Timeline Considerations
- Introduction and committee process: The bill has been introduced and referred to the House Judiciary Committee, indicating initial procedural steps for consideration, potential amendments, and hearings.
- Potential effective date: If enacted, the bill would specify an effective date for when the civil liability regime applies (often a future date or upon signing).
- Interaction with federal program: The bill would need to address potential conflicts or preemption with existing federal vaccine injury programs and statutes.
5) Practical Implications
- Access to civil relief for vaccine-injury claimants in West Virginia would be created or expanded, potentially increasing litigation against vaccine manufacturers.
- Manufacturers could face additional liability risk within the state, influencing risk management, insurance costs, and pricing considerations for vaccines.
- The bill could prompt industry and public health policy debates about balancing vaccine safety, public health goals, and avenues for compensation.
Note: The actual, precise text is not fully visible in the provided materials. For a complete and authoritative summary, the official bill text from the West Virginia Legislature should be consulted to confirm definitions, standards, defenses, damages, and procedural rules.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
